CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

CytomX Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$2.34+0.06 (+2.63%)

Close on Oct 19, 2026

Market cap: $512.32M
P/E (TTM): –
Dividend yield: –

CytomX Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31
Cash & Equivalents	13	38	17	194	206	192	188	248	178	106	61	64	8.70	15
Short-Term Investments	124	63	157	0	100	124	108	189	197	–	–	0	–	–
Cash & Short-Term Investments	137	102	175	96	266	256	279	436	374	182	187	64	8.70	15
Receivables	2.01	3.10	3.43	36	0.79	0.80	0.01	0.10	10	2.16	0.37	1.88	–	–
Prepaid Expenses & Other	4.86	3.58	5.00	7.47	4.29	7.10	7.18	9.25	4.35	3.90	2.30	0.48	–	–
Total Current Assets	144	107	183	237	310	324	303	445	389	188	190	67	–	–
Property, Plant & Equipment	1.30	2.47	3.96	5.07	5.96	6.95	7.37	6.93	4.22	4.39	3.48	3.02	–	–
Gross Property, Plant & Equipment	18	19	19	19	20	18	16	14	9.43	8.14	6.30	5.01	–	–
Accumulated Depreciation	-17	-16	-15	-14	-14	-11	-9.05	-6.95	-5.21	-3.74	-2.82	-1.99	–	–
Machinery & Equipment	–	–	–	14	15	14	12	10	7.16	–	–	–	–	–
Construction in Progress	0	0	0.37	0.71	0.31	0.25	0.24	0.79	0.02	–	–	–	–	–
Operating Lease Right-of-Use Assets	3.40	8.14	12	16	19	22	25	–	–	–	–	–	–	–
Goodwill	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	0.95	–	–
Intangible Assets	–	–	–	–	–	–	–	–	–	–	1.75	1.75	–	–
Other Long-Term Assets	0.03	0.07	0.08	0.03	0.90	2.17	2.02	1.38	1.36	2.97	0.36	0.49	–	–
Total Assets	152	121	202	261	339	359	341	457	398	199	197	73	–	–
Accounts Payable	1.30	1.09	1.46	2.81	2.82	3.00	4.16	5.13	4.21	6.60	4.70	1.92	–	–
Accrued Expenses	14	12	18	24	34	23	30	27	16	8.82	4.91	1.70	–	–
Current Portion of Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	1.42	–	–
Current Debt	–	–	–	–	–	–	–	–	–	–	–	1.42	–	–
Current Portion of Leases	4.24	5.15	4.59	4.08	3.62	3.20	2.81	–	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	–	–	–	–	13	0.00	–	–	–	–	–
Deferred Revenue (Current)	27	67	132	121	41	42	51	53	41	20	6.13	6.13	–	–
Total Current Liabilities	47	86	156	153	78	68	86	98	61	36	16	11	–	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	1.57	–	–
Long-Term Leases	0	4.24	9.39	14	18	22	25	–	–	–	–	–	–	–
Operating Lease Liabilities	4.24	9.39	14	18	22	25	28	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	–	–	–	–	–	–	–	0.51	0.51	0.50	–	–
Other Long-Term Liabilities	4.35	4.12	3.89	0	–	–	0.85	3.05	1.90	0.57	0.20	0.25	–	–
Total Liabilities	53	121	249	347	340	366	290	326	328	121	71	75	–	–
Total Debt	–	–	–	–	–	–	–	–	–	–	–	2.99	–	–
Preferred Stock	0	0	0	0	–	–	–	–	–	–	–	–	–	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	–	–
Additional Paid-In Capital	811	691	676	637	623	500	468	446	289	255	244	–	–	–
Retained Earnings	-712	-692	-723	-723	-624	-508	-443	-315	-219	-176	-117	-78	–	–
Comprehensive Income & Other	0.11	0.03	0.10	0.01	-0.24	-0.05	0.06	-0.09	-0.09	-0.03	-0.08	–	–	–
Shareholders' Equity	99	-0.46	-47	-86	-0.46	-7.77	25	136	70	78	126	-79	-44	-26
Total Equity	99	-0.46	-47	-86	-0.46	-7.77	25	136	70	78	126	-79	-44	-26
Total Liabilities & Equity	152	121	202	261	339	359	341	457	398	199	197	73	–	–
Shares Outstanding(shares)	170	80	67	66	65	48	46	45	38	36	36	1.00	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -476.2%
Net margin: -435.2%
Return on equity, FY2025: -35.2%

Financial strength

Current ratio: 9.36
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 43.2%

Valuation

P/E ratio: –
Price to sales: 27.99
Price to book: 1.70
Dividend yield: –